Sutro Biopharma Return on Equity

Sutro Biopharma (STRO) currently reports a ROE of 229.64%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Sutro Biopharma's ROE history and peer comparisons.

Sutro Biopharma's ROE of 229.64% is higher than the Healthcare sector average of 22.76%. That is roughly 908.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sutro Biopharma's current 229.64% should be judged against Healthcare norms (sector average: 22.76%) and against STRO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 229.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Sutro Biopharma, and consider following STRO for alerts when major investors trade the stock.

Sutro Biopharma is classified in the Healthcare sector. On ROE, it currently shows 229.64% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STRO with unrelated industries.